Oxford Biomedica plc (LON:OXB) Receives Average Rating of “Moderate Buy” from Analysts

Oxford Biomedica plc (LON:OXB) has been assigned a consensus rating of “Moderate Buy” from the seven brokerages that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 12-month target price among brokers that have covered the stock in the last year is GBX 687.

Several research firms recently issued reports on OXB. Deutsche Bank Aktiengesellschaft raised their price target on Oxford Biomedica from GBX 735 to GBX 800 and gave the company a “buy” rating in a report on Friday, January 9th. Stifel Nicolaus reaffirmed a “buy” rating and set a GBX 950 price target on shares of Oxford Biomedica in a research note on Wednesday, March 11th. Finally, Jefferies Financial Group assumed coverage on shares of Oxford Biomedica in a research report on Monday, March 23rd. They issued a “buy” rating and a GBX 827 price objective on the stock.

Oxford Biomedica Stock Performance

Oxford Biomedica stock opened at GBX 560 on Friday. The company has a debt-to-equity ratio of 116.74, a current ratio of 2.20 and a quick ratio of 1.67. The stock has a fifty day moving average price of GBX 702.33 and a two-hundred day moving average price of GBX 663.73. Oxford Biomedica has a 52-week low of GBX 232.50 and a 52-week high of GBX 952. The firm has a market capitalization of £676.88 million, a P/E ratio of -15.46 and a beta of 1.04.

Oxford Biomedica (LON:OXB) last issued its earnings results on Thursday, March 26th. The biopharmaceutical company reported GBX (26.92) EPS for the quarter. Oxford Biomedica had a negative net margin of 17.85% and a negative return on equity of 48.56%. As a group, analysts anticipate that Oxford Biomedica will post -31.0799998 EPS for the current fiscal year.

Oxford Biomedica Company Profile

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.